Three Hours of MSDH Approved Medical Cannabis CME !
Video Link's sent upon registration.
Questions: Jenny White ([email protected])

Disclosure Information

• In compliance with the ACCME and MSMA Standards for Commercial Support, today’s speakers, have asked me to advise you that they have no relevant financial relationships to disclose.

• Planners of this activity were also asked to disclose relevant financial relationships concerned with the content of this activity and they have nothing to disclose.

LEARNING OBJECTIVES

• General overview of this topic as a potential serious complication of MC use
• Endocannabinoid system review
• Neurotransmitter involvement
• Epidemiology
• Recognition/diagnosis
• Prevention/risk stratification
• Treatment
• Discuss the physiology of cannabis
• Become familiar with the available evidence surrounding cannabis use in vulnerable populations (specifically pregnancy-related use and in the adolescent population)
• Provide two known risks of cannabis use in these populations
• Overview the history of medical cannabis in the US
• Describe basic cannabis phytochemistry and the key relationships to products in legal and illicit markets
• Recognize elements of the endocannabinoid system and the pharmacological basis for positive or negative health impacts of THC
• Assess the pharmacology and pharmacokinetic behavior of THC when given by different routes of administration
• Understand how the products/limits allowable in the Mississippi Medical Cannabis Program compare to prescription cannabinoid dosing

The Mississippi State Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Mississippi State Medical Association designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.